Hospice CARE Act of 2026
Summary
HR7966 (Hospice CARE Act of 2026) proposes a 5-year nationwide moratorium on new Medicare hospice enrollment, but is in early legislative stages—referred to committee with only 2 cosponsors. No explicit funding, no near-term market impact. No public companies directly affected at this stage.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR7966 is an early-stage bill with no funding attached—near-term market impact is zero.
- 2.Only 2 cosponsors, no scheduled markups, and identical companion bill just referred to the Senate Finance Committee.
- 3.Existing hospice providers (no publicly traded pure plays of scale) would retain market positions; no ticker movement warranted.
Market Implications
No current market implications. The bill is procedural noise at this stage. If it advances out of committee, small-cap hospice operators and nursing home REITs with hospice exposure (e.g., $OHI, $WELL) would see minimal structural benefit from reduced new competition. No actionable information now.
Full Analysis
HR7966 was introduced on March 17, 2026, by Rep. Sánchez (D-CA) and referred to the House Committees on Ways and Means and Energy and Commerce. An identical companion bill, S4118, was introduced in the Senate. The bill is in early legislative stages—no hearings, markup, or floor votes scheduled. With only 2 cosponsors and procedural status, near-term passage probability is extremely low. The bill authorizes zero funding; it imposes a regulatory moratorium (a ban on new Medicare hospice provider enrollment for 5 years) with exemptions for underserved areas. No actual dollars are authorized or appropriated. No public companies are explicitly named or directly impacted by this bill at this stage. Hospice care is provided primarily by privately held entities and small regional nonprofits; public companies with hospice exposure (e.g., $CHE, $AMED) are not materially affected because the bill grandfathers existing providers and only halts new enrollment. If the bill advanced, it would structurally benefit existing providers by reducing competition, but at this procedural stage the market impact is negligible. Investors should monitor committee activity; no actionable trade signal currently exists.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Domestic Workers Bill of Rights Act
DELL FEDERAL SYSTEMS L.P: $1.0B Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $641M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $773M Department of Veterans Affairs Contract
OPTUM PUBLIC SECTOR SOLUTIONS, INC.: $598M Department of Veterans Affairs Contract
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.